Cynosure obtains FDA approval to market SculpSure for non-invasive lipolysis treatment
Cynosure, Inc. a leader in laser- and light-based aesthetic treatments, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market SculpSure, the world's first hyperthermic laser treatment for non-invasive lipolysis of the flanks.